How #MentalHealth disorders impact treatment decisions in localized #ProstateCancer . Yaw Nyame University of Washington & Joshua Cabral UChicago Urology join Ruchika Talwar Vanderbilt Urology to discuss their work published in Urology Practice > bit.ly/3vwj69f

Exploring the landscape of #mHSPC treatment in #NorthAmerica . Check out this insightful review on the implementation of treatment strategies and the importance of disease volume and timing of metastasis in guiding optimal therapy > bit.ly/3sBomr7 Zach Klaassen Rashid K. Sayyid

The #STEEL trial: Evaluating enzalutamide + ADT with salvage RT for high-risk recurrent #ProstateCancer . Edwin Posadas, MD Cedars-Sinai joins Zach Klaassen Georgia Cancer Center to discuss the complexities and aspirations of this trial > bit.ly/3V0Kd70

New imaging modalities like PSMA PET scans are game-changers for catching metastases traditional scans may miss. Zach Klaassen and Dr. Vahan Kassabian discuss how this technology has led to evolving treatment strategies on UroToday.com

Learn more - bit.ly/4buRp0f

Navigating #nmCRPC treatment in the PSMA PET era. Neal Shore, MD, FACS CURC joins Zach Klaassen Georgia Cancer Center to discuss this evolving landscape and delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. #WatchNow > bit.ly/3UHqk38

Exciting new data from #EAU24 on treatment for mCRPC patients:

The combination of a PARP inhibitor + an androgen receptor signaling inhibitor is showing efficacy as an initial treatment approach, especially for those with BRCA1 or BRCA2 mutations.

tinyurl.com/5yr76d68

Powerful results from a survey of partners reported at #EAU24 shed light on an often overlooked issue - the profound effect #prostatecancer has on patients' partners and spouses.

What are your thoughts on this important topic?

Precision risk assessment in #ProstateCancer : Growing utility in National Comprehensive Cancer Network (NCCN) Guidelines. Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center highlight the integration of the #Decipher Genomic Classifier tests across various stages of management > bit.ly/3JcSmya Decipher by Veracyte

National Comprehensive Cancer Network (NCCN) 2024 guidelines endorse novel prostate test for precision risk stratification. Rashid K. Sayyid and Zach Klaassen discuss updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification > bit.ly/43WX0tJ

Systematic review sheds light on treatment intensification in metastatic #ProstateCancer . Peter J. Goebell FAU Erlangen-Nbg and Zach Klaassen Georgia Cancer Center discuss if scientific evidence, as outlined in guidelines, translates into real-world practice changes > bit.ly/4ch0MSu

PARP inhibitor + AR signaling inhibitor combos improve #mCRPC outcomes in meta-analysis. Rashid K. Sayyid University of Toronto and Alicia Morgans, MD, MPH Dana-Farber discuss a systematic review and meta-analysis on combining PARP inhibitors with AR signaling inhibitors > bit.ly/43QaS9j

Long-term toxicity in #TesticularCancer and AYA: Premature mortality and morbidity illustrated. Zach Klaassen Georgia Cancer Center joins Alicia Morgans, MD, MPH Dana-Farber to discuss survivorship and the long-term effects. #WatchNow > bit.ly/3yaiaZD

The #BRCAAway Trial: Where combination treatment improves patient outcomes in #mCRPC . Dan George Duke Cancer & Zach Klaassen Georgia Cancer Center discuss the combination of PARP inhibitors and novel hormonal agents and the importance of genetic testing > bit.ly/49ldazj

An analysis in #NMIBC patients - a comparative study of white light and blue light cystoscopy in an equal access setting. Stephen B. Williams, MD, MBA, MS, FACHE UTMBUrology joins Zach Klaassen Georgia Cancer Center in this discussion on UroToday > bit.ly/47uDHYR Photocure BLC with Cysview® (hexaminolevulinate HCl)

For men with high-risk localized #prostatecancer , a new trial examined giving hormone therapy before surgery.

Watch the video to hear Zach Klaassen discuss the results: tinyurl.com/5yr76d68

Managing nonmetastatic castration-resistant #ProstateCancer . Zachary Reardon, MD joins Zach Klaassen Georgia Cancer Center to discuss the nuances of managing #nmCRPC in clinical practice. #WatchNow > bit.ly/43Q6KGr

#ARASENS subgroup analysis on triplet therapy improves outcomes for Black patients with #mHSPC . Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center join in this #JournalClub discussion on UroToday > bit.ly/3viSmcF The Oncologist

Epidemiology applied to focal therapy in #ProstateCancer : Where do we stand? Presentation by Kae Jack Tay. #AUA24 written coverage by Julian Chavarriaga > bit.ly/3WvNcoP Amer. Urol. Assn.

BCG unresponsive disease: How much risk can my patient tolerate? Roger Li and Sima Porten discuss as part of the #AUA24 IBCG #BladderCancerForum . Written coverage by Zach Klaassen University of Toronto > bit.ly/3Uv0Dmn

Very high-risk #NMIBC with variant histology. Presentation by Cookson, Michael University of Oklahoma Urology. #AUA24 written coverage by Zach Klaassen University of Toronto > bit.ly/4dtNwe0 Amer. Urol. Assn.